Browsing Tag
Central Drugs Standard Control Organisation
8 posts
Bajaj Healthcare (NSE: BAJAJHCARE) rallies 16% on Cenobamate approval milestone
BAJAJHCARE surged on India’s first Cenobamate recommendation. Final approval and launch economics must now justify the ₹1,183 crore valuation.
Medkart Pharmacy plans public quality report as India’s NSQ drug alerts more than double
Medkart Pharmacy is strengthening its Medkart Assured programme with plant audits, dual laboratory testing and plans to publish batch-testing and rejection data as scrutiny of medicine quality rises across India.
NATCO Pharma (NSE: NATCOPHARM) wins CDSCO approval for semaglutide as FDA compliance risks recede at its API unit
NATCO Pharma Limited secures CDSCO approval for semaglutide as U.S. FDA risks ease. Find out what this means for growth, execution, and investors.
Wockhardt sees Q2 revenue surge, driven by antibiotic innovation and biosimilar expansion
Wockhardt Limited, a leading pharmaceutical and biotechnology company, released its second-quarter financial results for the fiscal year 2024-25,…
BaroPace gets CDSCO approval for RelieveHFpEF-II clinical trial in India
BaroPace Inc., a medical technology company focused on developing pacemaker regulation techniques based on blood pressure, has been…
AstraZeneca Pharma India gets Dapagliflozin 10mg import and market permission from CDSCO
AstraZeneca Pharma India has secured an import and market permission for Dapagliflozin (Forxiga) tablets of 10 mg from…
Bharat Parenterals gets license and authorization for Favipiravir oral suspension for Covid treatment
Bharat Parenterals said that it has secured the license and authorization from Drugs Controller General of India (DCGI)…
Glenmark Pharmaceuticals launches FabiFlu for COVID-19 treatment in India
Glenmark Pharmaceuticals has secured approval from India to launch Japan-based Fujifilm’s antiviral drug favipiravir under the brand name…